Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study

详细信息    查看全文

• 作者：Nan Xu ; Fei Chen ; Fengliang Wang ; Xun Lu ; Xu Wang ; Mingming Lv ; Cheng Lu
• 关键词：Breast cancer ; lncRNA RP11 ; 445H22.4 ; Serum biomarker
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：36
• 期：10
• 页码：7659-7665
• 全文大小：818 KB
• 参考文献：1.De Santis C, Ma J, Bryan L, et al. Breast cancer statistics. CA Cancer J Clin. 2014;64(1):52-2.CrossRef
  2.Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-0.CrossRef
  3.Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19(8):1893-07.CrossRef
  4.Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426-7.CrossRef PubMed
  5.Mari? P, Ozreti? P, Levanat S, et al. Tumor markers in breast cancer—evaluation of their clinical usefulness. Coll Antropol. 2011;35(1):241-.PubMed
  6.Wu S, He Z, Zhou J, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88-3.CrossRef PubMed
  7.Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumor Biol. 2005;26(6):281-3.CrossRef
  8.Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-12.CrossRef PubMed
  9.Qiu MT, Hu JW, Yin R, et al. Long noncoding RNA: an emerging paradigm of cancer research. Tumor Biol. 2013;34(2):613-0.CrossRef
  10.Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31(43):4577-7.PubMed Central CrossRef PubMed
  11.Li H, Yu B, Li J, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5(8):2318-9.PubMed Central CrossRef PubMed
  12.Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409-9.PubMed Central CrossRef PubMed
  13.Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38-5.PubMed Central CrossRef PubMed
  14.Tong YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta. 2006;363(1):187-6.CrossRef PubMed
  15.Chevli KK, Duff M, Walter P, et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol. 2014;191(6):1743-.CrossRef PubMed
  16.Wang FL, Chen F. Effects of age, breast density and volume on breast cancer diagnosis: a retrospective comparison of sensitivity of mammography and ultrasonography in China’s rural areas. Asian Pac J Cancer Prev. 2013;14(4):2277-2.CrossRef PubMed
  17.Mitrovi? O, ?oki? V, ?iki? D, et al. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer. Target Oncol, 2013: 1-3.
  18.Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol. 2010;11(12):1193-.CrossRef PubMed
  19.DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-2.CrossRef PubMed
  20.Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet, 2013.
  21.Zhang H, Chen Z, Wang X, et al. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6(1):1-.CrossRef
  22.Gutschner T, H?mmerle M, Ei?mann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180-.PubMed Central CrossRef PubMed
  23.Prensner J R, Iyer M K, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet, 2013.
  24.Zhang EB, Han L, Yin DD, et al. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol. 2014;31(5):1-.
  25.Zhao Y, Guo Q, Chen J, et al. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep. 2014;31(1):358-4.PubMed
  26.Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108(12):2419-5.PubMed Central CrossRef PubMed
  27.Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-3.PubMed Central CrossRef PubMed
  28.English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013;17(2):85-9.PubMed Central CrossRef PubMed
  
• 作者单位：Nan Xu (1) (2)
  Fei Chen (1)
  Fengliang Wang (1)
  Xun Lu (3)
  Xu Wang (2)
  Mingming Lv (1)
  Cheng Lu (1) (2)
  
  1. Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, 210004, China
  2. First Clinical Medicine College, Nanjing University of Chinese Medicine, Nanjing, 210000, China
  3. Nanjing Jinling High School, Nanjing, 210000, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Long noncoding RNAs (lncRNAs) have been gradually confirmed to be tumor-associated biological molecules and became interesting new diagnostic targets of cancer. However, the clinical significances of most cancer-related lncRNAs are largely unknown. Here, we evaluated, for the first time, the feasibility and clinical significances of circulating serum lncRNA RP11-445H22.4 as biomarker for the detection of breast cancer (BC). In this study, the relative concentrations of breast cancer-associated lncRNA RP11-445H22.4 were investigated in a total of 136 serum samples by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). The correlations between the levels of serum lncRNA RP11-445H22.4 in breast cancer patients and the clinicopathological factors of these patients were further analyzed. Receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic values. In breast cancer patients, the expression level of lncRNA RP11-445H22.4 is significantly increased (p-lt;-.001). The sensitivity and specificity of RP11-445H22.4 for BC were 92 and 74 %, respectively. Its expression levels were correlated with estrogen receptor (ER), progesterone receptor (PR), and menopausal status of the breast cancer patients (p-lt;-.05). For the detection of breast cancer, the use of RP11-445H22.4 showed a remarkable improvement compared with the clinical serum carcinoembryonic antigen. In conclusions, lncRNA RP11-445H22.4 may be a new potential biomarker of breast cancer. Keywords Breast cancer lncRNA RP11-445H22.4 Serum biomarker